Julie Tinklenberg
Clinical Associate Professor, Psychiatry and Behavioral Sciences - Vaden Health Center
Bio
Dr. Julie Tinklenberg specializes in the treatment of mental illness in the university setting. She has worked in college mental health for over 15 years. Dr.Tinklenberg has a special interest in anxiety disorders, parenting issues, mood disorders and interpersonal/relationship problems.
Clinical Focus
- Psychiatry
Academic Appointments
-
Clinical Associate Professor, Psychiatry and Behavioral Sciences - Vaden Health Center
Professional Education
-
Board Certification: American Board of Psychiatry and Neurology, Psychiatry (2002)
-
Residency: Stanford University (2000) CA
-
Internship: Stanford University (1996) CA
-
Medical Education: UC Davis (1995) CA
All Publications
-
Criminal recidivism predicted from narratives of violent juvenile delinquents
CHILD PSYCHIATRY & HUMAN DEVELOPMENT
1996; 27 (2): 69-79
Abstract
Youth violence poses a major public health problem. It is important to find treatable predictors of recidivism. Our Subjects had committed offenses of physical and sexual assault. The personality dimensions of restraint and distress were rated by two independent and blind raters from narratives of offender's committing offenses, which were obtained at baseline during incarceration. Inter and intrarater kappas for each narrative were significant. In a 10-13 year follow-up, subjects lowest in self- restraint had significantly higher recidivism and their reoffenses differed in quality. Restraint may be influenced by clinical intervention and constitutes a new target in the treatment of delinquents.
View details for Web of Science ID A1996VP57900001
View details for PubMedID 8936793
-
CENTRAL ALPHA-1-ADRENOCEPTOR STIMULATION FUNCTIONALLY ANTAGONIZES THE HYPNOTIC RESPONSE TO DEXMEDETOMIDINE, AN ALPHA-2-ADRENOCEPTOR AGONIST
ANESTHESIOLOGY
1991; 75 (2): 252-256
Abstract
Previously, we demonstrated that dexmedetomidine, an alpha 2 agonist, produces a hypnotic-anesthetic response in rats via activation of central alpha 2 adrenoceptors and that this response could be enhanced by the alpha 1 antagonist prazosin. In the current experiment we investigated whether central alpha 1 adrenoceptor stimulation antagonizes the alpha 2 adrenoceptor-mediated hypnotic response. Cirazoline, an alpha 1 adrenoceptor agonist that partitions into the central nervous system, attenuated dexmedetomidine's hypnotic response whether administered systemically (0.3-1 mg.kg-1 intraperitoneally [ip]) or centrally (0.1 mg.kg-1 intracerebroventricularly). Prazosin, an alpha 1 adrenoceptor antagonist that effectively crosses the blood-brain barrier, fully blocked cirazoline's attenuating effect on dexmedetomidine-induced hypnosis, whereas doxazosin, which partitions poorly into the brain, did not block cirazoline's effect. Administration of phenylephrine, 0.3-3 mg.kg-1 ip, an alpha 1 adrenoceptor agonist that does not penetrate into the brain, did not attenuate dexmedetomidine's hypnotic effect. These results indicate that central alpha 1-adrenoceptor stimulation functionally antagonizes the hypnotic response to an alpha 2-adrenoceptor agonist. These data underscore the important requirement for alpha 2 adrenoceptor selectivity if these agonists are to be useful in the anesthetic setting.
View details for Web of Science ID A1991FZ70000013
View details for PubMedID 1677547
-
ANALYSIS OF ANESTHETIC ACTION ON THE POTASSIUM CHANNELS OF THE SHAKER MUTANT OF DROSOPHILA
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
1991; 625: 532-539
Abstract
Recent evidence suggest that exposure to volatile anesthetic agents causes a change in conductance through an undelineated potassium channel. With recently developed genetic and molecular techniques the Drosophila melanogaster (D.m.) genome can be manipulated to study the role that potassium ion channel function plays in anesthetic action. The IA potassium channel is encoded by the Shaker (Sh) locus on the X chromosome of D.m. Because this channel may be one of those involved in volatile anesthetic action, we tested the sensitivity to isoflurane in three Shaker strains with different degrees of dysfunctional IA conductance (Shnull greater than ShKS133 greater than Sh5). Anesthetic sensitivity was also examined in mutant strains of D.m. which express abnormalities either in other potassium channel conductances (eag, slo) or other ion conductances (para). The normally conducting wild type served as the control. Two-day-old adult D.m. were stimulated with a heat source during exposure to the volatile anesthetic isoflurane, and the number moving in response to the noxious stimulus was noted. After testing the Shaker and control strains at no fewer than 13 concentrations, the IC50S (isoflurane concentration in percent vol/vol at which 50% of the flies did not respond to the heat stimulus) were derived. The IC50 values for Sh 5 (0.89), Sh133 (1.29), and Shnull (1.37) were significantly different from the wild type (0.56). The rank order of insensitivity of these Shaker mutants corresponded to the extent of the alteration in IA conductance as established by previous studies in these mutants. Neither eag (0.66), para (0.48), nor slo (0.63) differed significantly from the wild type. These data suggest that the IA potassium channel plays a role in volatile anesthetic action.
View details for Web of Science ID A1991FZ45500060
View details for PubMedID 1905502
-
PERTUSSIS TOXIN AND 4-AMINOPYRIDINE DIFFERENTIALLY AFFECT THE HYPNOTIC ANESTHETIC ACTION OF DEXMEDETOMIDINE AND PENTOBARBITAL
ANESTHESIOLOGY
1990; 73 (2): 304-307
Abstract
Dexmedetomidine, a highly selective and potent agonist at alpha-2 adrenoceptors, produces a hypnotic-anesthetic action in rats. The mechanism for this response may involve an inhibitory G-protein and increased conductance through a potassium channel. To investigate this, the effects of pertussis toxin, a specific inactivator of inhibitory G-proteins, and 4-aminopyridine, a blocker of potassium channels, on the hypnotic-anesthetic response to dexmedetomidine were studied in rats. Pertussis toxin and 4-aminopyridine both decreased the hypnotic-anesthetic action of dexmedetomidine in a dose-dependent fashion. To preclude the possibility that pertussis toxin and 4-aminopyridine attenuated the hypnotic-anesthetic action of dexmedetomidine via indirect central nervous system excitation, the effects of pertussis toxin and 4-aminopyridine on the hypnotic-anesthetic action of pentobarbital also were assessed. Pentobarbital-induced hypnosis was not attenuated by either treatment. These results suggest that the receptor-effector mechanism for the hypnotic-anesthetic action of dexmedetomidine involves an inhibitory G-protein and increased conductance through a potassium channel.
View details for Web of Science ID A1990DV59100019
View details for PubMedID 1974396